silk route to the acceptance and re-implementation of bacteriophage therapy—part ii
Clicks: 291
ID: 241639
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
291 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #11 of 25 articles by views in derecho pucp
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.
| Reference Key |
therapy2018antibioticssilk
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Expert round table on acceptance and re-implementation of bacteriophage therapy;Wilbert Sybesma;Christine Rohde;Pavol Bardy;Jean-Paul Pirnay;Ian Cooper;Jonathan Caplin;Nina Chanishvili;Aidan Coffey;Daniel De Vos;Amber Hartman Scholz;Shawna McCallin;Hilke Marie Püschner;Roman Pantucek;Rustam Aminov;Jiří Doškař;D. İpek Kurtbӧke |
| Journal | derecho pucp |
| Year | 2018 |
| DOI |
10.3390/antibiotics7020035
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.